Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $72.28 USD
Change Today -1.04 / -1.42%
Volume 2.9M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Key Developments

Mylan Wins GBP 230 Million Multiple Contract for Supplying Generic Pharmaceuticals

Mylan won a GBP 230 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit for the supply of generic pharmaceuticals.

Mylan N.V. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM

Mylan N.V. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

Mylan May Consider Buying Teva

Mylan N.V. (NasdaqGS:MYL) is not willing to sell itself to Teva Pharmaceutical Industries Limited (NYSE:TEVA), Mylan’s Executive Chairman, Robert Coury said. The official added that the company would consider buying that company down the road. The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter Perrigo Company Public Limited Company (NYSE:PRGO). Teva made an unsolicited $40 billion bid for Mylan in April 2015, and it was rejected. Teva said recently that it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.

Mylan N.V. Enters into Amendment No. 1 to the Revolving Credit Agreement

On May 1, 2015, Mylan Inc. entered into Amendment No. 1 to the Revolving Credit Agreement dated as of December 19, 2014, among the Borower, Mylan N.V, certain lenders and issuing banks and Bank of America, N.A., as administrative agent. The Revolving Amendment provides that, following the closing of the company's offer for the entire issued and to be issued share capital of Perrigo Company plc, the financial covenant in the Revolving Credit Agreement will be modified as follows: (i) for the four fiscal quarters following the closing of the Perrigo Proposal, the company will be required to maintain a ratio of consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters not to exceed 4.75 to 1.00, (ii) for each of the subsequent two fiscal quarters, the company will be required to maintain a Leverage Ratio not to exceed 4.25 to 1.00, and (iii) for any fiscal quarter thereafter, the company will be required to maintain a Leverage Ratio not to exceed 3.75 to 1.00. The Revolving Amendment also amends the event of default provisions to provide that any change of control or change of control put rights under any indebtedness of Perrigo or its subsidiaries that are triggered as a result of the closing of the Perrigo Proposal will not result in an event of default so long as the company or its subsidiaries refinances such indebtedness within 30 days of the closing of the Perrigo Proposal or makes any change of control offer required by the terms of such indebtedness and purchases all notes validly tendered pursuant thereto, respectively.

Mylan Unveils Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 Mg/0.03 Mg in the US Market

Mylan NV announced the availability of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg in the US oral contraceptive market with immediate effect. The company stated that Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, is the generic version of Teva's Seasonale Tablets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $72.28 USD -1.04

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,834 JPY +26.50
Becton Dickinson and Co $140.51 USD -0.31
Perrigo Co PLC $194.31 USD +1.32
Shire PLC 5,510 GBp -100.00
WW Grainger Inc $241.96 USD +0.96
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 34.5x
Price/Sales 3.9x
Price/Book 4.0x
Price/Cash Flow 41.3x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.